X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16) 16
female (14) 14
male (14) 14
middle aged (12) 12
aged (11) 11
index medicus (11) 11
double-blind method (9) 9
risk factors (9) 9
coronary heart disease (8) 8
cardiac & cardiovascular systems (7) 7
cardiovascular (7) 7
drug therapy (7) 7
medical and health sciences (7) 7
medicin och hälsovetenskap (7) 7
abridged index medicus (6) 6
cardiovascular disease (6) 6
care and treatment (6) 6
clinical trials (6) 6
follow-up studies (6) 6
lipoprotein (6) 6
myocardial infarction (6) 6
treatment outcome (6) 6
activating-factor acetylhydrolase (5) 5
agriculture (5) 5
animal husbandry (5) 5
atherosclerosis (5) 5
benzaldehydes - administration & dosage (5) 5
benzaldehydes - adverse effects (5) 5
biocides, e.g. as disinfectants, as pesticides, as herbicides (5) 5
chemistry (5) 5
clinical medicine (5) 5
coronary disease - drug therapy (5) 5
fishing (5) 5
forestry (5) 5
human necessities (5) 5
hunting (5) 5
hygiene (5) 5
hypertension (5) 5
klinisk medicin (5) 5
medical or veterinary science (5) 5
metallurgy (5) 5
organic chemistry (5) 5
oximes - administration & dosage (5) 5
oximes - adverse effects (5) 5
pest repellants or attractants (5) 5
pharmacology (5) 5
plant growth regulators (5) 5
preparations for medical, dental, or toilet purposes (5) 5
preservation of bodies of humans or animals or plants or partsthereof (5) 5
risk (5) 5
steroids (5) 5
trapping (5) 5
1-alkyl-2-acetylglycerophosphocholine esterase - antagonists & inhibitors (4) 4
benzaldehydes - therapeutic use (4) 4
biological markers (4) 4
biomarkers (4) 4
blood pressure (4) 4
carbazoles - therapeutic use (4) 4
cardiac and cardiovascular systems (4) 4
coronary artery disease (4) 4
coronary disease (4) 4
coronary disease - mortality (4) 4
heart attacks (4) 4
hypertension - drug therapy (4) 4
kardiologi (4) 4
lipids (4) 4
oximes - therapeutic use (4) 4
phospholipase a (4) 4
phospholipase a2 inhibitors - administration & dosage (4) 4
phospholipase a2 inhibitors - adverse effects (4) 4
propanolamines - therapeutic use (4) 4
prospective studies (4) 4
research (4) 4
acute coronary syndromes (3) 3
antihypertensive agents - therapeutic use (3) 3
atherosclerotic plaque (3) 3
biomarkers - blood (3) 3
cardiology (3) 3
cardiovascular diseases (3) 3
cholesterol (3) 3
confidence intervals (3) 3
coronary vessels (3) 3
heart-disease (3) 3
inflammation (3) 3
inhibitor (3) 3
medicine (3) 3
mortality (3) 3
phospholipases (3) 3
1-alkyl-2-acetylglycerophosphocholine esterase - blood (2) 2
1-alkyl-2-acetylglycerophosphocholine esterase - metabolism (2) 2
acute coronary syndrome - drug therapy (2) 2
administration, oral (2) 2
adrenergic beta-antagonists - administration & dosage (2) 2
adrenergic beta-antagonists - therapeutic use (2) 2
antihypertensive agents - administration & dosage (2) 2
benzaldehydes (2) 2
benzaldehydes - pharmacokinetics (2) 2
beta blockers (2) 2
beta-blockers (2) 2
beta-blocking-agents (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Heart Journal, ISSN 0002-8703, 2010, Volume 160, Issue 4, pp. 655 - 661.e2
Journal Article
JAMA, ISSN 0098-7484, 09/2014, Volume 312, Issue 10, pp. 1006 - 1015
Journal Article
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Clinical Chemistry, ISSN 0009-9147, 01/2017, Volume 63, Issue 1, pp. 325 - 333
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0182115
Darapladib, a lipoprotein-associated phospholipase A2 (Lp-PLA(2)) inhibitor, failed to demonstrate efficacy for the primary endpoints in two large phase III... 
MULTIDISCIPLINARY SCIENCES | Phospholipase A2 Inhibitors - therapeutic use | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Middle Aged | Risk Factors | Oximes - therapeutic use | Male | Clinical Trials as Topic | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | 1-Alkyl-2-acetylglycerophosphocholine Esterase - genetics | Coronary Disease - genetics | Coronary Disease - metabolism | Phospholipase A2 Inhibitors - pharmacokinetics | 1-Alkyl-2-acetylglycerophosphocholine Esterase - antagonists & inhibitors | Coronary Disease - drug therapy | Female | Aged | Benzaldehydes - pharmacokinetics | Benzaldehydes - therapeutic use | Proteolipids | Care and treatment | Usage | Lipoproteins | Genetic aspects | Blood lipoproteins | Heart attack | Meta-analysis | Myocardial infarction | Heart | Heart attacks | Clinical trials | Lipids | Cardiovascular disease | Genomes | Risk factors | Confidence intervals | Odors | Mathematical analysis | Apolipoprotein E | Genetic analysis | Genetics | Population | Lipoprotein (low density) receptors | Bioinformatics | Heart diseases | Genotypes | Deoxyribonucleic acid--DNA | Enzymes | Medical research | Effectiveness | Phospholipase A2 | Diarrhea | Principal components analysis | Pharmacology | Stability analysis | Metabolism | Risk analysis | Gene expression | Minority & ethnic groups | Patients | Loci | Coronary artery disease | Medicine | Studies | Genetic variance | Phospholipase | Gene frequency | Coronary vessels | Alleles | Infarction | Cardiovascular diseases | Odor | Medical and Health Sciences | Medicin och hälsovetenskap | Deoxyribonucleic acid | DNA
Journal Article
American Heart Journal, ISSN 0002-8703, 2011, Volume 161, Issue 5, pp. 972 - 978
Journal Article